PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer
PRABITAS 研究设计:一项务实的随机 III 期临床试验,比较每两周一次的三氟尿苷/替吡嘧啶联合贝伐珠单抗与常规方案治疗转移性结直肠癌的疗效。
期刊:
影响因子:
doi:10.1016/j.esmogo.2024.100090
Sakakida, T; Masuishi, T; Asayama, M; Mitani, S; Makiyama, A; Shimura, T; Takeda, H; Suwa, Y; Takano, Y; Sawada, K; Yomoda, T; Mushiake, H; Okumura, Y; Yokota, M; Yamamoto, M; Kito, Y; Ogawa, K; Matsuoka, H; Ando, M; Tajika, M; Muro, K; Kudo, C; Mishima, A; Murotani, K; Taniguchi, H